Efficacy and safety of a short-course (12-week) de-escalated neoadjuvant regimen (weekly paclitaxel/trastuzumab/pertuzumab) in early HER2-positive breast cancer: Interim analysis of a prospective study.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Maxim Ruban, Larisa Bolotina, Andrey Kaprin
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162500446